Philadelphia skyline seen across the water

Doctors Said Elliana Hernandez Likely Wouldn’t Live Past 5. After a Drug Trial in Philadelphia, She’s Walking in a Gait Trainer and Has Said ‘Dada.’

Doctors told Tomas and Brenda Hernandez that their daughter Elliana likely would not live past age 5. Today she crawls, walks in a gait trainer, and has said her first word: “dada.”

The Phoenix-area family credits a drug trial in Philadelphia, according to AZFamily. They fly across the country on a regular basis so Elliana can take part.

What the Doctors Said

Elliana has pyruvate dehydrogenase complex deficiency, called PDCD for short, a rare and life-threatening condition that affects the brain and nervous system. Brenda first noticed something was off when Elliana was about 8 months old and was not rolling over, sitting up or holding her head up, AZFamily reported.

At about a year old, a doctor sent the family to a neurologist, and a genetic swab confirmed the condition. Both parents were tested as well. Tomas said the outlook was grim. “Statistics show, not past five years old is a thing for her,” he told the station.

What PDCD Does to a Child’s Body

In plain terms, children with PDCD cannot turn food into energy as well as other kids can. The National Organization for Rare Disorders says symptoms usually start in infancy and include poor feeding, low muscle tone, developmental delay and seizures.

A medical review on the National Library of Medicine’s bookshelf describes it as an inherited condition that mainly affects the brain. That review says a strict high-fat ketogenic diet is the standard treatment for now, and it lists the drug in Elliana’s trial, dichloroacetate or DCA, as still experimental.

Because the signs can look like ordinary delays at first, many families wait a while for answers. The same review says the median age at diagnosis is about 20 months, and that signs can show up anywhere from before birth to later in childhood.

Small Steps That Add Up

Over several months on the trial drug, Elliana went from not crawling to crawling, and then to walking in a gait trainer, a frame that supports a child who is learning to take steps. Then came her first word. According to AZFamily, it was “dada.”

The parents say they are sharing the story to raise awareness that PDCD can happen to any family.

The Long Trips to Philadelphia

AZFamily reported that the family travels from Phoenix to Philadelphia for the trial, which is a Phase 3 study of DCA that began earlier in 2026 and enrolled nearly three dozen children. The report does not name the hospital or the trial. A Phase 3 study of DCA in PDCD sponsored by Saol Therapeutics is listed on ClinicalTrials.gov, but the station did not say whether it is the one Elliana is in. That listing shows 34 children ages 6 months to 17 years and describes the study as active but no longer recruiting.

For a family with a young child, the travel is a real cost in time, money and routine. The parents describe the change they have seen at home: a daughter who was not crawling and now takes steps in her gait trainer.

What Could Change Next

The FDA has a decision date on DCA at the end of 2026, AZFamily said. Saol Therapeutics says the agency’s target date is Dec. 30, 2026, after it turned down the first application in August 2025 without naming safety or manufacturing concerns, according to the company. Saol says the disease has no FDA-approved therapies and can cause a serious energy shortage in the body, lactic acid buildup, major developmental problems and early childhood death.

The company also says that if the drug is approved, it would be paired with a genetic test that helps set each child’s dose. The company’s press release is its own account, and the FDA has not made its decision yet.

Tomas said approval would mean the family would no longer have to fly to Philadelphia, and treatment could be offered at local hospitals. Elliana would take the medicine for the long term, and any decision to stop would be the family’s to make, the station reported.

This article was produced with AI assistance and edited for accuracy against the sources linked above.

Image: Haimbd, CC0, via Wikimedia Commons

Similar Posts